ArticleObesity surgery2025
Impact of SGLT2 Inhibitors Use on Risk of Postoperative Acute Kidney Injury Following Metabolic and Bariatric Surgery: A Retrospective Study.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations.Frontiers in cardiovascular medicine · 2026Review
- Association between iron deficiency anemia and the risk of new-onset tuberculosis infection: a matched cohort analysis.Frontiers in nutrition · 2026Article
- Impact of zinc deficiency on mortality risk in patients with chronic obstructive pulmonary disease: a retrospective analysis.Frontiers in nutrition · 2025Article
- Perioperative Dexmedetomidine Exposure and One-Year Mortality Risk After Video-Assisted Thoracoscopic Surgery: A Multi-Institutional Study.Drug design, development and therapy · 2025Article
- Prognostic role of baseline hemoglobin level for long-term mortality in newly diagnosed rheumatoid arthritis: a cohort study.Frontiers in nutrition · 2025Article
- Iron deficiency anemia and the risk of new-onset tinnitus in female patients: a cohort study.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated whether preoperative use of sodium-glucose cotransporter 2 inhibitors (SGLT2is), known for their cardio-renal benefits in type 2 diabetes (T2DM), reduces postoperative acute kidney injury (AKI) after metabolic and bariatric surgery (MBS).
methodsThe TriNetX research network was used to analyze propensity-matched patients with T2DM who underwent MBS between 2010 and 2024. We compared patients who received SGLT2is (discontinued ≥ 1 week before surgery) with those using other antidiabetic medications. The primary outcome was AKI within 30 days after surgery. Secondary outcomes included risks of mortality, intensive care unit (ICU) admission, acute myocardial infarction/stroke, eGFR decline to < 60 mL/min/1.73 m
resultsAfter matching, 4364 patients were included (n = 2182 for each group). The incidence of AKI was identical between the groups (1.88% in both, OR 1.00, 95% CI 0.65-1.55, P = 1.00). No significant differences were observed in mortality, ICU admission, acute myocardial infarction/stroke, eGFR decline to < 60 mL/min/1.73 m
conclusionsPreoperative SGLT2is use in patients undergoing MBS is associated with a reduced risk of GFR decline in those with longer-duration diabetes, suggesting potential renoprotective benefits. No increased risk of adverse outcomes was observed when these medications were discontinued ≥ 1 week before surgery.
Indexed as
Identifiers
40736663What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.